Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

View/Open

Supporting information (63.31Kb)

Publication Date

2017-02

ICR Author

Popat, Sanjay

Marsden,

Author

Juan, O

Popat, S

Type

Journal Article

Metadata

Show full item record

URL

https://repository.icr.ac.uk/handle/internal/1161

Collections

• Clinical Studies

Version of record

10.1016/j.lungcan.2016.11.007

Subject

Humans

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Pyrazoles

Pyridines

Proto-Oncogene Proteins

Protein Kinase Inhibitors

Neoplasm Staging

Treatment Outcome

Protein-Tyrosine Kinases

Genetic Testing

Molecular Targeted Therapy

Biomarkers, Tumor

Crizotinib

Research team

Thoracic Oncology

Language

eng

Date accepted

2016-11-10

License start date

2017-02

Citation

Lung cancer (Amsterdam, Netherlands), 2017, 104 pp. 131 - 133